A Phase 2 study of nivolumab in combination with modified FOLFIRINOX for metastatic pancreatic cancer.

ABSTRACT:

Background

Nivolumab with modified FOLFIRINOX (mFOLFIRINOX) may have additive antitumour effects while minimising chemotherapy cytotoxicity. We assessed the efficacy and safety of nivolumab+mFOLFIRINOX in metastatic pancreatic cancer.

Methods

Thirty-one treatment-naïve patients aged ≥20 years with metastatic unresectable/recurrent pancreatic cancer (≥1 measurable lesion per Response Evaluation Criteria in Solid Tumours version 1.1) and Eastern Cooperative Oncology Group 0/1 score and life expectancy ≥90 days received nivolumab (480 mg, every 4 weeks) plus mFOLFIRINOX. The primary endpoint was objective response rate (ORR). Secondary endpoints included overall survival (OS), progression-free survival (PFS) and safety.

Results

At the median follow-up of 13.4 months, the

SUBMITTER: Morizane C 

PROVIDER: S-EPMC11524122 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature